上海交通大学学报（医学版）

›› 2011, Vol. 31 ›› Issue (5): 598-.doi: 10.3969/j.issn.1674-8115.2011.05.016

• 论著（临床研究） • 上一篇    下一篇

候选基因单核苷酸多态性与胃癌患者卡培他滨联合紫杉醇化疗后生存期的关系

郑磊贞1, 顾建春1, 龚继芳3, 李小平1, 陈思宇1, 章 莉1, 焦晓栋2, 王杰军2   

  1. 1.上海交通大学 |医学院附属新华医院肿瘤科, 上海 200092； 2.第二军医大学附属长征医院肿瘤科, 上海 200003； 3.北京肿瘤医院消化内科, 北京 100142
  • 出版日期:2011-05-28 发布日期:2011-05-27
  • 通讯作者: 王杰军, 电子信箱: jiejunw@csco.org.cn。
  • 作者简介:郑磊贞（1965—）, 女, 主任医师, 硕士生导师；电子信箱: zhengleizhen2006@126.com。
  • 基金资助:

    上海市卫生局基金（2008135）

Relationship between single nucleotide polymorphisms of candidate genes and survival of patients with gastric cancer undergoing chemotherapy with capecitabine and paclitaxel

ZHENG Lei-zhen1, GU Jian-chun1, GONG Ji-fang3, LI Xiao-ping1, CHEN Si-yu1, ZHANG Li1, JIAO Xiao-dong2, WANG Jie-jun2   

  1. 1.Department of Oncology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China；2.Department of Oncology, Changzheng Hospital, The Second Military Medical University, Shanghai 200003, China；3.Department of Digestive Diseases, Beijing Cancer Hospital, Beijing 100142, China
  • Online:2011-05-28 Published:2011-05-27
  • Supported by:

    Shanghai Municipal Health Bureau Foundation, 2008135

PDF (PC)

1719

摘要：

目的 探讨热点候选肿瘤相关基因的单核苷酸多态性（SNPs）与胃癌患者卡培他滨联合紫杉醇化疗后生存期的关系。方法 收集93例经病理学检查确诊的胃癌患者，采用卡培他滨联合紫杉醇为主的方案进行化疗。用TaqManMGB探针进行原癌基因TP53 rs1042522（G/C）、代谢相关基因GSTP1 rs1695（A/G）和CYP11B2 rs1799998（T/C）以及DNA损伤修复相关基因XRCC1 rs1799782（C/T）和ERCC2 rs1799793（G/A）的基因分型。比较不同基因型患者化疗后中位生存时间（MST）及各种因素对预后的影响。结果 对93例患者的中位随访时间为29.6个月，MST为34.93个月。TP53 rs1042522（G/C）多态性位点与胃癌患者化疗后的MST相关，携带TP53 rs1042522野生基因型G/G组的MST为51.2个月，而携带变异基因型（G/C+C/C）组的MST为26.6个月，经log-rank检验两组间差异无统计学差异,但较为接近（P=0.073）；其他基因多态性与MST无显著相关性（P>0.05）。Cox回归分析显示性别、手术和病理分期是影响胃癌患者化疗预后效果的主要影响因素。结论 TP53（rs1042522 G/C）位点基因多态性与用药效果呈临界相关，进一步的验证还需要扩大样本。

关键词: 胃癌, DNA修复基因, 单核苷酸多态性, 卡培他滨, 紫杉醇

Abstract:

Objective To investigate the relationship between single nucleotide polymorphisms of tumor-associated candidate genes and survival of patients with gastric cancer undergoing chemotherapy with capecitabine and paclitaxel. Methods Ninety-three patients pathologically confirmed of gastric cancer were selected, and received chemotherapy with capecitabine and paclitaxel. Genotypes of protooncogene TP53 rs1042522 (G/C), metabolism-associated gene GSTP1 rs1695(A/G) and CYP11B2 rs1799998 (T/C), DNA repair-associated gene XRCC1 rs1799782 (C/T) and ERCC2 rs1799793 (G/A) were determined by TaqMan-MGB methods. The median survival time (MST) after chemotherapy was compared among patients with different genotypes, and influencing factors for prognosis were analysed. Results The median time of follow-up was 29.6 months, and MST was 34.93 months. TP53 rs1042522 (G/C) genotype was related to MST after chemotherapy, and patients with TP53 rs1042522 G/G genotype were borderline significantly higher than those with TP53 rs1042522 G/C+C/C genotype in MST (51.2 months vs 26.6 months, P=0.073). There was no significant correlation between the other gene polymorphisms and MST (P>0.05). Cox regression analysis revealed that gender, operation status and pathological staging were the main influencing factors for the prognosis of gastric cancer after chemotherapy. Conclusion Polymorphisms of TP53 (rs1042522 G/C) are marginally significantly associated with prognosis in patients with gastric cancer after chemotherapy with capecitabine and paclitaxel.

Key words: gastric cancer, DNA repair gene, single nucleotide polymorphism, capecitabine, paclitaxel